MGC Pharmaceuticals

MGC Pharmaceuticals, now rebranded as Argent BioPharma, is a biopharmaceutical company focused on developing cannabis-based medicines and treatments. Its key product offerings include CannEpil, a CBD-based liquid formula for treating epilepsy; CogniCann, a CBD-THC formula for treating dementia and Alzheimer's disease; and CimetrA, an anti-inflammatory medicine that can potentially treat the human immune system's cytokine response to Covid-19.

The company's affordable line of cannabis-derived medicines, MP, has Pharma-grade compounds ranging from high CBD to high THC formulations. MGC Pharmaceuticals has conducted successful clinical trials for its anti-inflammatory medicine, with a Phase 2 trial reporting a 100% recovery rate among 50 participants receiving its phyto-cannabinoid treatment for Covid-19.

The company is focused on three main areas of research – neurology, oncology, and autoimmune diseases. It has established research partnerships with leading universities to develop its cannabinoid medicines for various ailments. MGC Pharmaceuticals acquired the clinical and medical research company MediCaNL in April 2021 to design, manage, and run its future clinical trials.

In February 2021, MGC Pharmaceuticals became the first medicinal cannabis company to be admitted to the London Stock Exchange (LSE) after raising USD 11.6 million in an IPO from sophisticated and institutional investors. As of February 2024, the company was restructuring and embracing a new biopharmaceutical era, leveraging advancements in polypharmacology and nanotechnology while remaining committed to its existing cannabis-based products.